Objectives. The population-level incidence of vocal fold paralysis after thyroidectomy for well-differentiated thyroid carcinoma (WDTC) is not known. This study aimed to measure longitudinal incidence of postoperative vocal fold paralyses and need for directed interventions in the Medicare population undergoing total thyroidectomy for WDTC.
W hether due to improved diagnostic testing, 1 scrutiny, 2 or a real increased disease burden, 3 thyroid carcinoma remains the only noncutaneous head and neck malignancy that continues to increase in incidence, 4 almost tripling in the past 30 years from 3.6 in 100,000 in 1973 to 11.9 in 100,000 in 2007. 5, 6 Well-differentiated thyroid carcinoma (WDTC) is the indication for 50% of the 80,000 thyroid surgeries performed annually in the United States. 7, 8 An increase in thyroidectomies, not surprisingly, has been associated with more postoperative complications. In fact, surgical manipulation is responsible for 46% and 56% cases of unilateral (UVFP) and bilateral vocal fold paralysis (BVFP), 9 respectively, which often result in severe dysphonia, 10 dysphagia, 11 and dyspnea. 12 Most thyroidectomies occur in patients less than 65 years of age. 13 However, prevalence of thyroid nodules, the typical presenting symptom of carcinoma, does increase with age, with an estimated 50% of patients over 65 years of age having nodules on ultrasound examination. 14, 15 Importantly, the malignant potential of nodules appears to increase with advancing age. 15, 16 As a result, thyroidectomies have burgeoned in the Medicare population over the past decades. More surgeries lead to more attributable vocal fold paralyses, which have major detrimental effects on quality of life, 17 substantially increase morbidity and medical costs, 18 and often require surgical intervention.
Recent epidemiological studies report postthyroidectomy UVFP and BVFP rates of 0.85% to 3.5% and 0.35% to 2.3%, respectively. 7, [19] [20] [21] [22] [23] [24] [25] [26] However, to date, there are no population-based estimates of vocal fold paralysis incidence after total thyroidectomy for WDTC in the Medicare population. The current study aims to fill that void by measuring the longitudinal incidence of postoperative vocal fold paralyses and need for directed interventions in Medicare beneficiaries undergoing total thyroidectomy for WDTC.
Methods
The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and was approved by the Vanderbilt Institutional Review Board (IRB No. 111775).
SEER-Medicare Data
Patients were identified from the combined SEER-Medicare database. SEER is a national cancer surveillance tool that merges 17 population-based tumor registries capturing 26% of cancers diagnosed in the United States. 27 SEER is linked to Medicare, which is a government-funded entity that manages 95% of insurance claims of the US population aged 65 years and older. 28 
Cohort Selection
To be included, patients had a total thyroidectomy on a known date for pathologically confirmed WTDC diagnosed between 1991 and 2007 and had uninterrupted enrollment in Medicare Part A and B based on age being 65 years or older. WDTC was defined as papillary, follicular, or medullary histopathology. Patients with other histologic types of thyroid cancer (eg, anaplastic, lymphoma, metastases, melanoma) were excluded, as were those with preoperative diagnoses of vocal fold paralyses ( Table 1) . Non-WDTC histologic types of cancer were excluded due to differences in their aggressiveness, staging, and treatment.
Outcomes and Variables
The primary outcome measures were (1) postoperative vocal fold paralysis and (2) interventions to treat these conditions. All treatments directed at paralyses were extracted. Treatment of BVFP includes tracheotomy and cordotomy/ arytenoidectomy procedures. UVFP treatments are categorized into temporary or permanent. Temporary intervention primarily includes injection medialization procedures, while permanent treatments are laryngoplasty with or without arytenoid adduction and reinnervation procedures ( Table 1) . Additional data accessed from SEER-Medicare were patient characteristics (gender, race, age), socioeconomic status (SES), registry geographic region, practice setting (large metropolitan, metropolitan, urban, less urban, rural), 27 cancer characteristics (diagnosis date, histologic type, SEER historic stage), and date of total thyroidectomy. SES was estimated using the 2000 census tract median household income for the zip code of each patient's residence. Median incomes were divided into quartiles for analysis. The 17 SEER registries were divided into geographic regions: Western (California, Washington), Southwestern (Utah, New Mexico), Midwestern (Iowa, Michigan), Southern (Kentucky, Louisiana, Georgia), Northeastern (Connecticut, New Jersey), and Hawaii. SEER historic staging was used because American Joint Commission on Cancer staging data were inconsistently recorded during the study period. Use of intraoperative recurrent laryngeal nerve monitoring during thyroidectomy was identified from Medicare claims ( Table 1 ).
Data Analysis
All data management and analysis were done using SAS version 9.2 (SAS Institute Inc, Cary, North Carolina) and STATA/MP version 12.1 software (STATACorp, College Station, Texas). Vocal fold paralysis was the primary outcome analyzed, while secondary analyses considered UVFP and BVFP separately. Longitudinal postoperative vocal fold paralyses (overall, UVFP, BVFP) and intraoperative nerve monitoring (IONM) utilization rates were calculated. Interventions to treat these conditions were extracted and reported. The need for intervention was used as a surrogate for those paralyses causing severe or persistent enough symptoms (eg, permanent paralyses) to warrant surgical treatment. Durations from thyroidectomy to (1) paralysis diagnosis and (2) directed treatment were calculated and reported as medians and interquartile ranges (IQRs) due to the nonparametric nature of these data.
Univariate analyses were performed using pairwise t tests, chi-square tests, and logistic regression as appropriate.
Stepwise multivariate logistic regression analyses were used to identify independent risk factors for postthyroidectomy vocal fold paralyses. A significance level of P \ .20 was the criterion for inclusion in multivariate models, although P \ .05 was required for statistical significance.
Results
Of 10,225 Medicare beneficiaries with uninterrupted Part A and B coverage diagnosed with WDTC between 1991 and 2009, 5670 (55%) met inclusion criteria and underwent total thyroidectomy ( Figure 1) . The cohort was 69% female and 85% Caucasian and had a mean age of 73.7 years (95% confidence interval [CI], 73.6-73.9). Of histologic types of WDTC, papillary was most common (81.8%), followed by follicular (14.7%) and medullary (3.5%).
Univariate Analysis
Overall, 9.5% of Medicare beneficiaries undergoing total thyroidectomy for WDTC were diagnosed with postoperative vocal fold paralysis (annual incidence 6.1%-16.0%; Figure 2 ). The rate of these complications decreased 5% annually between 1991 and 2009 (odds ratio [OR] 0.95; 95% CI, 0.93-0.97; P \ .001). Diagnosis was made a median 5.6 months postoperatively (IQR 0.9-17).
In unadjusted analysis, older age, male gender, non-Caucasian race, geographic region, and stage were all associated with significantly increased odds of vocal fold paralysis ( Table 2) . Odds increased 3% with each additional year of age among Medicare patients who had thyroidectomy performed. For stage, rate of paralysis was 4.5% if localized to the thyroid, 13.7% if there was regional extension, and 22.4% if there was regional extension with lymph node involvement. In all, 22% (n = 119) of patients diagnosed with vocal fold paralysis required surgical intervention, which occurred a median 8.5 months after thyroidectomy (IQR 2.4-27).
UVFP was diagnosed after 8.2% of total thyroidectomies for WDTC (annual incidence 5.7%-13.2%; Figure 2 ), a median 5.6 months postoperatively (IQR 0.9-16). There was a 4% annual reduction in UVFP rate between 1991 and 2009 (OR 0.96; 95% CI, 0.94-0.99; P \ .001). In this Medicare cohort, the unadjusted odds of UVFP increased with each additional year of age, male gender, non-Caucasian race, and advancing cancer stage, while being significantly increased in specific geographic regions ( Table 3) . Overall, 1.7% (n = 98) of those who underwent total thyroidectomy for WDTC or 21% of patients diagnosed with UVFP were subsequently treated with temporary injection medialization (10.3%, n = 48), type I laryngoplasty with or without arytenoid adduction (7.3%, n = 34), or both (3.4%, n = 16). Directed treatment was initiated a median 8.5 months postthyroidectomy (IQR 2.5-27).
BVFP was diagnosed after 1.3% of total thyroidectomies for WDTC (annual incidence 0.34%-4.8%; Figure 2 ) within a median 6.7 months postoperatively (IQR 0.76-33). There was a 9% annual reduction in rate of BVFP diagnosis between 1991 and 2009 (OR 0.91; 95% CI, 0.87-0.95; P \ .001). In unadjusted analysis, rates of BVFP were significantly increased with higher stage and were increased in specific geographic regions ( Table 4 ). Only 0.37% (n = 20) of those who underwent total thyroidectomy for WDTC or 28% of patients diagnosed with BVFP required subsequent tracheotomy (8.2%, n = 6), cordotomy/arytenoidectomy procedures (5.5%, n = 4), or both (13.7%, n = 10). Directed surgery occurred a median 9 months postthyroidectomy (IQR 1.7-55).
In this cohort, IONM was introduced during total thyroidectomy in 1992, and its application increased 5-fold (3%-15%) between 2001 and 2009. IONM increased 22% annually during the period of study (OR 1.22; 95% CI, 1.18-1.26). Overall, 9.9% of total thyroidectomies (n = 562) were done with IONM. It was used most commonly in the Northeastern region (15%) followed by Western (10.8%), Southern (9.1%), Southwestern (6.0%), Hawaiian (5.3%), and Midwestern regions (3.2%). There was no difference in overall rate of vocal fold paralysis based on IONM use (no IONM 9.6% vs IONM 8.4%; P = .33) nor were there differences when stratified by UVFP (no IONM 8.3% vs IONM 7.3%; P = .40) and BVFP (no IONM 1.3% vs IONM 1.1%; P = .63).
Multivariate Analysis
In multivariable modeling, odds of postthyroidectomy vocal fold paralysis were found to be independently associated with age, race, stage, and geographic region. Odds of vocal fold paralysis increased 3% for each additional year of age in this Medicare population ( Table 5 ). Non-Caucasian race increased overall odds of paralysis 41%. Higher stage was associated with significantly higher odds of developing a paralysis. Follicular histologic type was most favorable compared with papillary and medullary types, which had significantly higher odds of these complications. When compared with localized disease, regional extension or regional extension with lymph node involvement was associated with 3.3-and 5.8-fold increased odds of paralysis, respectively. Patients undergoing total thyroidectomy in the Western and Southwestern regions had significantly higher odds of vocal fold paralysis when referenced against those in Southern registries. Results were similar when stratified into UVFP and BVFP (Tables 6 and 7, respectively).
Discussion
This is the first report on national longitudinal incidence of postthyroidectomy vocal fold paralyses in the Medicare population with WDTC. The overall 9.5% mean annual incidence (8.2% UVFP, 1.3% BVFP) of postthyroidectomy vocal fold paralysis translates into nearly 1:10 Medicare patients experiencing these complications. Incidence of vocal fold paralyses decreased 5% annually between 1991 and 2009. The reason for decline is unclear. A plausible explanation is that over time, a higher proportion of thyroidectomies are being performed for smaller, less aggressive cancers, thus resulting in less risk of iatrogenic injury. It has also been proposed that IONM reduces the risk of recurrent laryngeal nerve injury and that its increased use has effectively decreased postthyroidectomy vocal fold paralyses. 29, 30 However, our findings do not support this second assertion.
Effect of Intraoperative Nerve Monitoring
The use of IONM during thyroidectomy is a hotly debated topic. The use of IONM in this cohort began in 1992, it was used sparingly (0%-3%) until 2000, and thereafter its use increased 5-fold by 2009. Since the introduction of IONM more than 30 years ago, 3 its use has increased, yet to date there have been no studies on longitudinal trends in the use of IONM. Our results suggest that use of IONM has increased over time, but to what degree this has occurred in the United States requires further population-based longitudinal assessment that includes patients less than 65 years of age.
Overall, 9.9% of total thyroidectomies in this cohort were done in conjunction with IONM (range, 0% in 1991 to 15% in 2009). Adoption of this technology was the focus of a 2007 survey which found that the majority of US otolaryngologists (71.4%) did not regularly use IONM in their practices. 32 More recent studies of the use of IONM indicate that 53% of general surgeons and up to 65% of head and neck surgeons use IONM in some thyroidectomies. 33, 34 Interestingly, a 2013 national epidemiologic study from Denmark reported that IONM was used in 79% of thyroidectomy procedures over a similar time period. 24 Our study was not able to show a statistically robust association between IONM and reduced risk of vocal fold paralysis, which is consistent with the majority of prior investigations into this relationship. 21, 24, [35] [36] [37] [38] However, the reason for the wide discrepancy in utilization rates between this and other recent studies is unclear. Several possibilities exist. First, capturing the use of IONM in administrative data requires accurate and complete coding, which usually improves if coding results in improved reimbursement. 39, 40 Thus, it is possible that IONM was used and not properly coded for, depending on practice and reimbursement patterns. If this is true, the study method could have underestimated its use. Second, the present study may be a more accurate representation of IONM use as it derives from population-based data and was not subject to biases inherent in surveys of ''expert'' experience. The recent American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guideline on improving voice after thyroid surgery systematically reviewed the research on IONM and found equipoise between benefit and nonutility. 41 Research must identify circumstances in which IONM can consistently impart statistically significant, reduced risk of vocal fold paralysis. Until then, it should be considered an option 41 or an adjunct to the gold standard of direct recurrent laryngeal nerve identification during thyroid surgery.
High Rates of Vocal Fold Paralysis
Postthyroidectomy UVFP and BVFP incidences are higher in this study than the conventionally cited 0.85% to 3.5% and 0.39% to 2.3%, respectively. 7, [19] [20] [21] [22] [23] [24] [25] [26] The explanation is multifactorial. First, this study used Medicare claims data, which resulted in a more representative estimation of population disease burden than many previous epidemiological studies that were primarily limited to single-institution case series of tertiary care experience. 22 Second, population risk is higher since all total thyroidectomies were performed for carcinoma. 24, 25, 42 Third, increased risk in our cohort may relate to the population's advanced age, which was found to be an independent risk factor for UVFP. Increased age has been cited as a predictive factor for recurrent laryngeal nerve paralyses in several studies 23, 24, 43 and refuted in others. 7, 44 Older age has been linked to increased malignant potential of nodules, 15, 16 and differentiated thyroid carcinomas in elderly patients tend to behave more aggressively with more extrathyroidal spread and distant metastases. 45 Thus, transitively, age may be a surrogate for cancer aggressiveness, which in turn may increase the odds of vocal fold paralyses. In this analysis, however, age remained a risk factor even after adjustment for cancer stage. However, the most plausible explanation for the high rates is a preponderance of temporary paralyses. This is supported by the finding that only a fraction of patients diagnosed with postthyroidectomy UVFP and BVFP underwent directed intervention: 21% and 28%, respectively. Supporting this hypothesis is a systematic review that analyzed 27 studies with over 25,000 cumulative thyroidectomy patients and found 9.8% and 2.3% mean incidences of temporary and permanent postthyroidectomy vocal fold paralyses, 22 rates that are nearly identical to those in the present study (9.5% overall, 2.1% ''permanent''/requiring intervention). More reinforcing evidence is gained from studies that actively examined patients immediately postoperatively from thyroidectomy and reported rates similar to those herein (4.9%-8.4%). 46, 47 Interestingly, Bergenfelz et al 23 found that the odds of vocal fold paralysis increased 1.9-fold in Scandinavian departments that routinely perform postoperative laryngoscopy even in the absence of symptoms. This finding substantiates that early diagnostic testing will identify temporary paralyses that may not necessarily be symptomatic or require intervention, and it demonstrates how ascertainment bias can complicate incidence estimates. Contrastingly, several large epidemiological studies of postthyroidectomy vocal fold paralysis from Europe found temporary rates between 2.0% and 3.9%. [23] [24] [25] [26] Godballe et al 24 recently evaluated the national experience in Denmark, where it is routine to perform laryngoscopy in the immediate postoperative period, and reported temporary and permanent rates of 2.6% and 2.2%. 24 While these incidences are lower than reported in our study, they must be taken in context. None of these population-level studies were limited to total thyroidectomies performed strictly for malignancy in an aged population. In fact, those studies that analyzed subpopulations similar to ours found similarly that there was a significantly higher risk of vocal fold paralysis in those who had thyroidectomy for malignancy (5.7%-9.0% rate of UVFP) 24, 25 or were in higher age strata 23, 24 (2% increase with each additional year or age thyroidectomy was performed; adjusted OR 1.02 vs 1.03 current cohort). 23 Further supporting the assertion that high incidences derive from a preponderance of temporary paralyses are the 5.6-and 8.5-month and 6.7-and 9-month median times to diagnosis and treatment for UVFP and BVFP patients, respectively. These times closely coincide with conventional teaching that recurrent laryngeal nerve recovery takes between 6 and 12 months. 48 Thus, we expect that delays in diagnosis were largely intentional, as many practitioners prefer to wait to determine whether the vocal fold paralysis and associated symptoms will resolve (ie, are temporary) or will persist and require intervention.
AAO-HNS clinical practice guidelines on improving voice after thyroid surgery strongly recommend referring patients for vocal fold evaluation if symptoms persist longer than 2 weeks to 2 months. 41 Directed and effective interventions are readily available to reduce an unnecessarily prolonged period of symptoms and reduced quality of life. In fact, opting for a temporary vocal fold injection versus conservative management in the treatment of UVFP may reduce the need for subsequent permanent intervention. 49 Unfortunately, the majority of the Medicare cohort was not expeditiously referred for vocal fold assessment to head off troublesome voice, 10 swallowing, 11 and breathing sequelae. 12 
Limitations
Several study limitations deserve mention. This study was performed in Medicare beneficiaries with WDTC. Most thyroidectomies are done in those under 65 years of age. 13 Thus, results may not be applicable to a younger population or those having total thyroidectomy for benign indications. Additionally, data from large administrative databases are inherently subject to errors in coding and sampling and to reporting biases. During the period of study, SEER expanded from 13 to 20 sites. Systematic differences in treatment strategies based on new registries' experience add heterogeneity that could affect results. However, correlational analyses were unable to detect any clear systematic differences based on added sites. In addition, an a priori decision was made to only consider total thyroidectomy procedures. The rationale was that several codes and descriptions are used for partial thyroidectomies thereby producing confusing heterogeneity that cannot be clarified using available claims data.
Conclusions
Annual rates of postthyroidectomy vocal fold paralyses are longitudinally decreasing among Medicare beneficiaries with WDTC. High incidence in this aged population is likely due to a preponderance of temporary paralyses, which is supported by the need for directed intervention in less than a quarter of affected patients. Further population-based studies are needed to refine the population incidence and risk factors for paralyses in the aging population.
